
Opinion|Videos|October 6, 2023
EMERALD Trial: Elacestrant for ER+/HER2- Metastatic Breast Cancer
Author(s)Rebecca A. Shatsky, MD
A review of results from the EMERALD trial investigating elacestrant in patients with ESR1-mutated metastatic breast cancer.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
3
Pelareorep Offers Promise in Second-Line KRAS-Mutant Metastatic CRC
4
Phase 3 Data Highlight Orca-T’s Clinical Benefits in Heme Malignancies
5











































